The RAS inhibitor rigosertib has been shown to block AKT activation and synergize with anti-PD-1/anti-CTLA-4 in B16F10 (NRASWTBRAFWT) and YUMM3.3 (BRAF-mutant) melanoma preclinical models [54]. Here, CTLA4 is linked to melanoma.